Molecule intelOpportunity: ModerateEssential

Nifedipine

38 brands · 14 companies · product forms

ATC: C08CA05

Opportunity snapshot

Launch attractiveness
47
Market saturation
40
Price room
100
Regulatory risk
0
38
brands
14
companies
Rs 426.44
median price
40
price points
20.24x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 16%

Price room

Across observed sources and strengths
CheapestRs 96.05
MedianRs 426.44
Most expensiveRs 1,943.71
Spread20.24×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 20.24x across 40 trusted points (Rs 96.05-1943.71). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 11 live products for Nifedipine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(60) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

14 canonical companies and 38 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 20.24x across 40 trusted points (Rs 96.05-1943.71). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.